MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is expanding its AI-driven voice analytics platform to include fatigue detection, complementing its existing drug and alcohol impairment screening capabilities. The company announced the development of a fatigue recognition system using speech analytics and proprietary artificial intelligence models on May 11, according to a news release (https://ibn.fm/4KNzG).
The fatigue prediction module will be integrated into MindBio’s planned Edge AI Intoxication Detection Kiosks, which are designed for high-risk workplace environments such as mining, aviation, transportation, and construction. These kiosks aim to provide a non-invasive alternative to traditional breath, saliva, blood, and laboratory-based testing systems. The company has filed a patent application covering the detection of neurologically active substances and fatigue through voice analysis.
Management stated that commercial testing of the kiosk hardware and software remains on track for late Q2 2026. The expansion into fatigue detection is significant because fatigue is a major safety concern in industries where operator alertness is critical. By adding this capability, MindBio’s platform could help employers identify impaired workers before they engage in safety-sensitive tasks, potentially reducing accidents and improving overall workplace safety.
MindBio Therapeutics is a biotechnology company commercializing AI-driven voice technology for intoxication detection. The company’s platform analyzes voice patterns to identify signs of drug or alcohol impairment, and now fatigue. The fatigue detection system uses speech analytics and proprietary AI models to predict states of fatigue, which can be as dangerous as intoxication in high-risk environments.
The initial sectors targeted for deployment include mining, aviation, transportation, and construction. These industries often require workers to operate heavy machinery or perform tasks that demand high levels of concentration. Non-invasive testing methods like voice analysis could streamline safety protocols and reduce downtime associated with traditional testing.
MindBio’s move to incorporate fatigue detection positions its technology as a comprehensive solution for workplace impairment monitoring. As the platform advances toward commercialization, it may attract interest from companies seeking to enhance their safety programs. For more information about MindBio Therapeutics, visit the company’s newsroom at https://ibn.fm/MBQIF.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is MindBio Therapeutics Expands AI Voice Platform with Fatigue Detection Module for High-Risk Workplaces.